Cosentyx is a biologic drug used to treat autoimmune diseases such as psoriasis and psoriatic arthritis. The active ingredient in Cosentyx is secukinumab [1]. According to Drugs.com, secukinumab is classified as a pregnancy category B drug, which means that animal studies have not shown any fetal harm, but there is not enough data available on human studies [2].

A recent study published in the Journal of Psoriasis and Psoriatic Arthritis reviewed the safety of Cosentyx during pregnancy and breastfeeding. The study concluded that there is limited data available on the safety of Cosentyx during pregnancy, but the available data does not suggest any significant harm to the fetus. However, the study recommends that Cosentyx should only be used during pregnancy if the potential benefits outweigh the potential risks [3].

It is important to note that Cosentyx is a prescription drug and should only be used under the guidance of a healthcare provider. Women who are pregnant or planning to become pregnant should discuss the potential risks and benefits of using Cosentyx with their healthcare provider before starting or continuing treatment [2,3].

In conclusion, the available data on the safety of Cosentyx during pregnancy is limited. However, animal studies have not shown any fetal harm, and the available human data does not suggest any significant harm to the fetus. Women who are pregnant or planning to become pregnant should discuss the potential risks and benefits of using Cosentyx with their healthcare provider before starting or continuing treatment [2,3].

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[2] https://www.drugs.com/pregnancy/secukinumab.html
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7874874/